Developed by the Patient Advisory Group, this session explores important topics affecting persons living with hepatitis B virus (HBV) infection, including:

• Hepatocellular carcinoma (HCC) surveillance
• New American Association for the Study of Liver Diseases HBV guidelines
• Emerging diseases such as hepatitis D virus and Met-HBV
• Unique challenges of treating chronic hepatitis B and coinfections
• Barriers to surveillance and treatment

Many patients with liver cancer do not receive a referral to a multidisciplinary liver tumor board—especially not in a timely manner. This may result in misdiagnosis, unnecessary diagnostic testing that delays the diagnosis, and/or delayed or failure to initiate recommended treatments.

Presenters explore what multidisciplinary liver tumor boards are and how they streamline the diagnosis and treatment of patients with liver cancer. Key topics include what makes a great multidisciplinary liver tumor board, and why multidisciplinary care is so important in liver cancer. Speakers aim to increase awareness of and access to multidisciplinary liver tumor boards and multidisciplinary care for all persons living with liver cancer.

As liver care becomes increasingly digital, expanded access to medical records, clinical notes, and artificial intelligence (AI)–supported tools is reshaping how patients understand and engage in their care. When integrated thoughtfully, these tools have the potential to improve clarity, support earlier recognition of disease patterns, and enhance patient-clinician communication. At the same time, increased transparency and patient-facing AI tools can introduce complexity. Variability in interpretation, over-reliance on automated insights, and inconsistent digital access may affect how information is understood and discussed in clinical encounters.

The session centers the patient navigation experience within modern hepatology practice. Faculty examine how individuals living with liver disease access and interpret digital health information; what AI–supported diagnostic tools can and cannot reliably provide; and how clinicians and patients can navigate conversations when AI–generated interpretations enter the exam room. Presenters focus particular attention on how these benefits and risks manifest across rural and urban care environments, where differences in infrastructure, specialty access, and digital resources may influence implementation and patient experiences. Speakers aim to provide a balanced, clinically grounded framework for integrating digital transparency and tools into liver disease care while preserving safety and trust.

Join this thought-provoking session which addresses key questions and approaches to overcome social and medical stigma to improve outcomes for persons living with alcohol-associated liver disease (ALD). Utilizing a panel that includes both clinical and patient perspectives, the discussion addresses key topics including:

• How to get the conversation started around alcohol use
• How to address mental health challenges for patients who drink alcohol
• How to talk about changes in ALD treatment
• Reasons why silence/hiding drinking is still so prevalent (not dishonesty but a survival mechanism against social and medical stigma)

Join this informative session that focuses on the use of dietary supplements, herbal products, and over-the-counter remedies and their impact on liver health with particular attention on drug-induced liver injury (DILI). The program brings together patient, caregiver, and physician perspectives to help attendees better understand the real-world risks supplements may pose—especially for people living with alcohol-associated liver disease (ALD), metabolic dysfunction–associated steatotic liver disease (MASLD), and those who have received a liver transplant.

The session includes a patient or caregiver sharing their lived experience with supplement use, highlighting the challenges individuals face. Clinicians discuss how supplements can affect the liver, common warning signs of injury, and why early recognition and open communication are critical. Speakers also address gaps in awareness, access to accurate information, and the importance of clear, nonjudgmental conversations between patients, caregivers, and health care practitioners. The session concludes with a moderated panel and audience question-and-answer period focused on practical strategies to support safer choices and shared decision-making.

This interactive, patient-centered session is designed to elevate knowledge, confidence, and engagement around liver health, liver disease, and liver cancer. Program presenters aim to empower patients, caregivers, and advocates by providing clear, accessible education about how the liver functions, why liver health matters to overall well-being, and how individuals can take an active role in prevention, treatment, and decision-making.

Through a combination of foundational education, storytelling, expert insight, and collaborative discussion, participants gain a deeper understanding of the liver's essential role in the body and the real-world impact of liver disease. Session presenters intentionally blend science with lived experience to create a welcoming environment where attendees feel informed, supported, and motivated to apply what they learn.

The program begins with a brief introduction and an interactive icebreaker followed by a focused educational segment that introduces the liver as a "superhero" organ, highlighting key functions and common misconceptions. The keynote presentation deepens understanding through impactful storytelling, followed by a moderated panel discussion featuring diverse perspectives from patients, clinicians, and advocates. The program provides attendees with practical knowledge, increased health literacy, and actionable strategies to support liver health and informed conversations with health care teams.

This informal introductory expert session orients learners to the field of health services research (HSR) and quality improvement (QI). Faculty provide an overview of what HSR and QI are, why they matter, and how they are used to improve the quality, accessibility, and fairness of health care. Using a few cases, presenters walk through practical considerations for launching HSR and QI projects, including framing the right questions, choosing the best study design, identifying collaborators/stakeholders, and considerations for data analysis and dissemination of findings. Additional considerations include technical aspects, such as obtaining certification in HSR/QI, and specific resources that attendees may need at their institution to complete the work. This session is ideal for trainees, early-career researchers, and established researchers who are new to HSR/QI or considering them as areas of focus.

Take advantage of this opportunity to discuss the genetic underpinnings of metabolic dysfunction–associated steatotic liver disease (MASLD) with topic experts. Faculty address and review the genetic risk and protective factors for MASLD onset, development, and progression. Presenters also highlight the role of genetic risk scores in MASLD.

Risk stratification in chronic liver disease is evolving from static fibrosis staging toward dynamic prediction of cirrhosis progression, portal hypertension, and clinical decompensation. Learn from topic experts who examine how established and emerging noninvasive tools—using a physiology-driven approach—can more accurately capture the determinants of disease progression. Disscussants integrate conventional serum and elastography-based noninvasive tests with emerging hemodynamic imaging, including magnetic resonance flow models (eg, magnetic resonance phase contrast vastly undersampled imaging with projection reconstruction; MR PC-VIPR) to highlight their complementary roles in assessment of portal hypertension and decompensation risk.

Through expert commentary and case-based discussion, participants examine how combining structural and functional biomarkers can improve prediction of first decompensation, adverse clinical outcomes, and therapeutic responses. Faculty emphasize practical application, limitations of current evidence, and future directions for incorporating advanced noninvasive tools into longitudinal patient management and accelerating outcome-driven clinical trials in cirrhosis.

Women living with liver disease often have concerns not experienced by men with liver disease. Join experts to discuss women's health among those living with liver disease. Faculty discuss and review the role of estrogens in liver disease; the impact of liver disease in the safe use of contraception and hormone replacement therapy; and pregnancy and family planning.